-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR / Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., December 14, 2020 (GLOBE NEWSWIRE) – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene drugs for serious disease, today announced the receipt of a Bill & Melinda Gates Foundation research grant in vivo gene editing therapies for the treatment of HIV.

“While we have demonstrated the promise of CRISPR / Cas9 gene editing ex vivo in sickle cell anemia and beta thalassemia, a in vivo hematopoietic stem cell editing approach could allow the transformative advantage of CRISPR / Cas9 to reach a wider range of patients, including those in low-resource settings who lack sufficient infrastructure for cell transplantation strains, ”said Tony Ho, MD, executive vice president and head of Research & Development at CRISPR Therapeutics. “We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV. “

The grant builds on CRISPR Therapeutics’ proprietary CRISPR / Cas9 gene editing technology and expertise in hematopoietic stem cell editing and contributes to efforts to accelerate transformative drugs for global health.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based drugs for severe disease using its proprietary CRISPR / Cas9 platform. CRISPR / Cas9 is a revolutionary gene editing technology that enables precise and directed modifications of genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs in a wide range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies such as Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly owned US subsidiary. , CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and sales offices in San Francisco, California and London, UK. For more information, please visit www.crisprtx.com.

CRISPR forward-looking statement
This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding expectations of CRISPR Therapeutics on all or part of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development and commercial potential of the technologies and therapies of editing of CRISPR / Cas9 genes. Without limiting the foregoing, the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that these statements are based on reasonable assumptions within the limits of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results of preclinical studies; whether the results of a preclinical trial will be favorable and predictive of the future results of future trials; uncertainties regarding regulatory approvals to conduct testing or market products; that future competitive or other market factors could adversely affect the commercial potential of CRISPR Therapeutics’ product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the protection of the intellectual property of the technology and the intellectual property of CRISPR Therapeutics belonging to third parties, and the outcome of proceedings (such as interference, opposition or similar proceedings) involving all or part of this intellectual property; and the risks and uncertainties described under “Risk Factors” in CRISPR Therapeutics’ most recent annual report on Form 10-K, the quarterly report on Form 10-Q, and in any subsequent filing made by CRISPR Therapeutics with the US Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Existing and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. CRISPR Therapeutics disclaims any obligation or commitment to update or revise any forward-looking statements contained in this press release, except to the extent required by law.

CRISPR THERAPEUTICS® The word mark and logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor contact:
Susan kim
+ 1-617-307-7503
[email protected]

Media contact:
Rachel Eides
WCG on behalf of CRISPR
+ 1-617-337-4167
[email protected]



Source link

About The Author

Related Posts

Leave a Reply

Your email address will not be published.